Information Provided By: 
Fly News Breaks for February 24, 2020
ESPR
Feb 24, 2020 | 09:13 EDT
JPMorgan analyst Jessica Fye says the label for Esperion Therapeutics' Nexletol is largely as anticipated. However, the drug-drug interaction language around use with higher doses of Zocor and Pravachol "represents a negative on the margin, though not a game-changer," Fye tells investors in a research note. The analyst expects investors to focus on initial script trends and whether they will support revenue expectations. Fye, who has lingering commercial questions based on efficacy, keeps a Neutral rating on Esperion shares.
News For ESPR From the Last 2 Days
There are no results for your query ESPR
